BR181-ED-THB6

Molecular Breast Imaging: An Adjunct Diagnostic Modality for Breast Cancer Evaluation

Thursday, Dec. 3 12:45PM - 1:15PM Location: BR Community, Learning Center Station #6



Gaiane M. Rauch, MD, PhD, Houston, TX (Presenter) Nothing to Disclose
Beatriz E. Adrada, MD, Houston, TX (Abstract Co-Author) Nothing to Disclose
Monica L. Huang, MD, Houston, TX (Abstract Co-Author) Nothing to Disclose
Rosalind P. Candelaria, MD, Houston, TX (Abstract Co-Author) Nothing to Disclose
Elsa M. Arribas, MD, Houston, TX (Abstract Co-Author) Nothing to Disclose
Wei T. Yang, MD, Houston, TX (Abstract Co-Author) Researcher, Hologic, Inc
Kelly Cox, BS, RT, Houston, TX (Abstract Co-Author) Nothing to Disclose
Lumarie Santiago, MD, Houston, TX (Abstract Co-Author) Nothing to Disclose
Srinivas C. Kappadath, PhD, Houston, TX (Abstract Co-Author) Research Grant, General Electric Company
TEACHING POINTS

Molecular Breast Imaging (MBI) generates functional images based on physiological processes within breast tissue, while conventional breast diagnostic imaging is based on anatomy and morphology. MBI can improve detection of multifocal and multicentric breast cancer, allow detection of contralateral breast cancer and may lead to change in patient's management. MBI can be used for an early assessment of tumor's response to neoadjuvant chemotherapy (NAC) and indicate if treatment should be altered or prolonged in order to achieve optimal response prior to surgery. MBI can be used for assessment of residual cancer burden after NAC and help in correct surgical planning, segmentectomy versus mastectomy.

TABLE OF CONTENTS/OUTLINE

MBI principles, physiological mechanisms, imaging techniques. MBI lexicon, diagnostic accuracy and radiation dose. Role of MBI for initial staging of the breast cancer. Use of MBI for assessment of tumor response to NAC and residual disease before surgery. Comparison of MBI with other breast imaging modalities. MBI challenges and advantages.